REPLIGEN CORP acquired ARTeSYN Biosolutions Holdings Ireland Limited for ~$200 million (~$130M cash + ~$70M in Repligen stock), a transaction completed in December 2020, structured as combination (cash plus stock).
ARTeSYN Biosolutions Holdings Ireland Limited operates in Systems / Chromatography & Filtration, is based in Ireland (with U.S. operations), had revenue of about ~$30 million projected annual revenue. Acquisition of ARTeSYN Biosolutions, a maker of gold-standard single-use downstream bioprocessing systems including automated chromatography and filtration systems with unique single-use flow-path designs. The deal advanced Repligen's Systems strategy in Filtration and Chromatography, complementing TangenX flat-sheet cassettes and OPUS pre-packed columns. ARTeSYN was projected to generate ~$30 million in revenue.
Hunt said 'the addition of ARTeSYN Biosolutions and Non-Metallic Solutions further strengthens our Systems offering. The ARTeSYN portfolio expands on the market success of our hollow-fiber and flat-sheet products.'
Gold-standard single-use downstream bioprocessing systems anchoring the Systems franchise. Complements TangenX cassettes and OPUS columns; advances single-use Systems strategy. Repligen Systems
The addition of ARTeSYN Biosolutions and Non-Metallic Solutions further strengthens our Systems offering. The ARTeSYN portfolio expands on the market success of our hollow-fiber and flat-sheet products.Tony J. Hunt, President and CEO, Repligen
We have made tremendous progress over the last four years as we introduced automated, highly efficient chromatography and filtration systems with unique flow path designs.Michael Gagne, Founder and CXO, ARTeSYN Biosolutions
Advisory firms were not disclosed for this transaction.